Clinical Trial Update: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Bevacizumab in combination with Anetumab Ravtansine or Paclitaxel for refractory ovarian, fallopian tube, or primary peritonea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Endometrioid Adenocarcinoma
• Fallopian Tube High Grade Serous Adenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian High Grade Serous Adenocarcinoma
• Peritoneal High Grade Serous Adenocarcinoma
• Platinum-resistant Fallopian Tube Carcinoma
• Platinum-resistant Ovarian Carcinoma
• Platinum-resistant Primary Peritoneal Carcinoma

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)
• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING